These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7791517)

  • 21. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.
    Pert A; Rosenblatt JE; Sivit C; Pert CB; Bunney WE
    Science; 1978 Jul; 201(4351):171-3. PubMed ID: 566468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential alteration in striatal dopaminergic and cortical serotonergic receptors induced by repeated administration of haloperidol or centbutindole in rats.
    Gulati A; Srimal RC; Dhawan BN
    Pharmacology; 1988; 36(6):396-404. PubMed ID: 2901759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J; Devanand DP; Carey RJ
    Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of single and long-term administration of nifedipine on dopamine-related behaviors.
    Maiolini Júnior M; Mattia NF; Conceição IM; Chang YH; Smaili S; Frussa-Filho R
    Braz J Med Biol Res; 1994 Mar; 27(3):725-30. PubMed ID: 8081297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lithium effects on estrogen-induced dopaminergic supersensitivity in rats.
    Dorce VA; Palermo-Neto J
    Brain Res Bull; 1992 Aug; 29(2):239-41. PubMed ID: 1525677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol releasing polymers.
    Köhler U; Schröder H; Augustin W; Sabel BA
    Neurosci Lett; 1994 Mar; 170(1):99-102. PubMed ID: 8041522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat.
    Rupniak NM; Hall MD; Mann S; Fleminger S; Kilpatrick G; Jenner P; Marsden CD
    Biochem Pharmacol; 1985 Aug; 34(15):2755-63. PubMed ID: 4040370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracerebroventricular administration of cholecystokinin reduces stereotypy in dopamine-supersensitive rats.
    Tieppo CA; Silva AM; Palermo-Neto J; Nasello AG; Felicio LF
    Braz J Med Biol Res; 1995 Mar; 28(3):351-4. PubMed ID: 8520531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of apomorphine administration on locomotor activity of control and experimental rats withdrawn from long-term haloperidol treatment.
    Bernardi MM; Palermo-Neto J
    Gen Pharmacol; 1983; 14(5):545-7. PubMed ID: 6685669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetic analysis of central nervous system supersensitivity induced in rats by long-term haloperidol administration. I. pA2 determination.
    Palermo-Neto J; Bernardi MM; Saban R
    Pharmacology; 1984; 28(4):203-10. PubMed ID: 6539476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haloperidol- and SCH23390-induced dopaminergic supersensitivities are not additive in the rat.
    Parashos SA; Barone P; Marin CA; Paraschos AJ; Kapitzoglou-Logothetis V; Chase TN
    Psychopharmacology (Berl); 1989; 98(2):189-92. PubMed ID: 2569216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diltiazem suppresses apomorphine-induced fighting and pro-aggressive effect of withdrawal from chronic ethanol or haloperidol in rats.
    Pucilowski O; Kostowski W
    Neurosci Lett; 1988 Oct; 93(1):96-100. PubMed ID: 3211374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
    Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
    Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroleptic treatment for a substantial proportion of adult life: behavioural sequelae of 9 months haloperidol administration.
    Waddington JL; Gamble SJ
    Eur J Pharmacol; 1980 Oct; 67(4):363-9. PubMed ID: 7192633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Further dopaminergic supersensitivity to dopamine agonists by subchronic administration of haloperidol in rats treated with colchicine.
    Kamata K; Okuyama S; Hashimoto S; Aihara H; Kasuya Y
    Jpn J Pharmacol; 1986 Oct; 42(2):329-32. PubMed ID: 3795627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypophysectomy does not prevent development of striatal dopamine receptor supersensitivity induced by repeated neuroleptic treatment.
    Jenner P; Rupniak NM; Hall MD; Dyer R; Leigh N; Marsden CD
    Eur J Pharmacol; 1981 Nov; 76(1):31-6. PubMed ID: 6119220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term administration of (-)deprenyl (selegiline), a compound which facilitates dopaminergic tone in the brain, leaves the sensitivity of dopamine receptors to apomorphine unchanged.
    Timar J; Knoll B; Knoll J
    Arch Int Pharmacodyn Ther; 1986 Dec; 284(2):255-66. PubMed ID: 3103558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
    Gordon JH; Diamond BI
    Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum.
    Allen RM; Lane JD; Brauchi JT
    Eur J Pharmacol; 1980 Jul; 65(2-3):313-5. PubMed ID: 7190503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of single and long-term droperidol administration on open-field and stereotyped behavior of rats.
    Frussa-Filho R; Palermo-Neto J
    Physiol Behav; 1991 Oct; 50(4):825-30. PubMed ID: 1775558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.